To the Editor: The analysis of prostate cancer–specific and overall survival by Dr Lu-Yao and colleagues1 concluded that primary androgen deprivation therapy (PADT) offered no benefit compared with conservative management in elderly men with localized prostate cancer. Since their comparison was based on epidemiologic data rather than those obtained in a prospective randomized trial, there is a possibility that confounding variables may have influenced patient outcomes.
Laufman L. Primary Androgen Deprivation Therapy in Men With Prostate Cancer. JAMA. 2009;301(1):35. doi:10.1001/jama.2008.903